Lesaffre E - Search Results

1

A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.

Dejardin D, Lesaffre E, Hamberg P, Verweij J. Dejardin D, et al. Among authors: lesaffre e. Pharm Stat. 2014 May-Jun;13(3):196-207. doi: 10.1002/pst.1618. Epub 2014 Apr 9. Pharm Stat. 2014. PMID: 24715683

2

Joint modeling of progression-free survival and death in advanced cancer clinical trials.

Dejardin D, Lesaffre E, Verbeke G. Dejardin D, et al. Among authors: lesaffre e. Stat Med. 2010 Jul 20;29(16):1724-34. doi: 10.1002/sim.3918. Stat Med. 2010. PMID: 20572123

3

Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects.

Dejardin D, Delmar P, Warne C, Patel K, van Rosmalen J, Lesaffre E. Dejardin D, et al. Among authors: lesaffre e. Pharm Stat. 2018 Mar;17(2):169-181. doi: 10.1002/pst.1843. Epub 2017 Dec 28. Pharm Stat. 2018. PMID: 29282862

4

Modified power prior with multiple historical trials for binary endpoints.

Banbeta A, van Rosmalen J, Dejardin D, Lesaffre E. Banbeta A, et al. Among authors: lesaffre e. Stat Med. 2019 Mar 30;38(7):1147-1169. doi: 10.1002/sim.8019. Epub 2018 Oct 25. Stat Med. 2019. PMID: 30360016

5

Stochastic EM algorithm for doubly interval-censored data.

Dejardin D, Lesaffre E. Dejardin D, et al. Among authors: lesaffre e. Biostatistics. 2013 Sep;14(4):766-78. doi: 10.1093/biostatistics/kxt019. Epub 2013 May 30. Biostatistics. 2013. PMID: 23728851

6

Including historical data in the analysis of clinical trials: Is it worth the effort?

van Rosmalen J, Dejardin D, van Norden Y, Löwenberg B, Lesaffre E. van Rosmalen J, et al. Among authors: lesaffre e. Stat Methods Med Res. 2018 Oct;27(10):3167-3182. doi: 10.1177/0962280217694506. Epub 2017 Feb 21. Stat Methods Med Res. 2018. PMID: 28322129 Free PMC article.

7

The power prior with multiple historical controls for the linear regression model.

Banbeta A, Lesaffre E, van Rosmalen J. Banbeta A, et al. Among authors: lesaffre e. Pharm Stat. 2022 Mar;21(2):418-438. doi: 10.1002/pst.2178. Epub 2021 Dec 1. Pharm Stat. 2022. PMID: 34851549

8

A note on non-parametric ANCOVA for covariate adjustment in randomized clinical trials.

Lesaffre E, Senn S. Lesaffre E, et al. Stat Med. 2003 Dec 15;22(23):3583-96. doi: 10.1002/sim.1583. Stat Med. 2003. PMID: 14652862

9

Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.

Qi H, Rizopoulos D, Lesaffre E, van Rosmalen J. Qi H, et al. Among authors: lesaffre e. Pharm Stat. 2022 Sep;21(5):818-834. doi: 10.1002/pst.2195. Epub 2022 Feb 6. Pharm Stat. 2022. PMID: 35128780 Free PMC article.

10

Baseline and treatment effect heterogeneity for survival times between centers using a random effects accelerated failure time model with flexible error distribution.

Komárek A, Lesaffre E, Legrand C. Komárek A, et al. Among authors: lesaffre e. Stat Med. 2007 Dec 30;26(30):5457-72. doi: 10.1002/sim.3083. Stat Med. 2007. PMID: 17910009

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters